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Summary
 
Many tumor-associated antigens are nonmutated, poorly immunogenic tissue differentiation
antigens. Their weak immunogenicity may be due to “self”-tolerance. To induce autoreactive T
cells, we studied immune responses to gp100/pmel 17, an antigen naturally expressed by both
normal melanocytes and melanoma cells. Although a recombinant vaccinia virus (rVV) encod-
ing the mouse homologue of gp100 was nonimmunogenic, immunization of normal C57BL/6
mice with the rVV encoding the human gp100 elicited a specific CD8
 
1
 
 T cell response. These
lymphocytes were cross-reactive with mgp100 in vitro and treated established B16 melanoma
upon adoptive transfer. To understand the mechanism of the greater immunogenicity of the
human version of gp100, we characterized a 9-amino acid (AA) epitope, restricted by H-2D
 
b
 
,
that was recognized by the T cells. The ability to induce specific T cells with human but not
mouse gp100 resulted from differences within the major histocompatibility complex (MHC)
class I–restricted epitope and not from differences elsewhere in the molecule, as was evidenced
by experiments in which mice were immunized with rVV containing minigenes encoding
these epitopes. Although the human (hgp100
 
25–33
 
) and mouse (mgp100
 
25–33
 
) epitopes were ho-
mologous, differences in the three NH
 
2
 
-terminal AAs resulted in a 2-log increase in the ability
of the human peptide to stabilize “empty” D
 
b
 
 on RMA-S cells and a 3-log increase in its ability
to trigger interferon 
 
g
 
 release by T cells. Thus, the fortuitous existence of a peptide homologue
with significantly greater avidity for MHC class I resulted in the generation of self-reactive T
cells. High-affinity, altered peptide ligands might be useful in the rational design of recombi-
nant and synthetic vaccines that target tissue differentiation antigens expressed by tumors.
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he recent cloning of tumor antigens recognized by T
cells has caused considerable interest in the develop-
ment of antigen-specific cancer vaccines (1–3). Some anti-
gens are especially attractive candidates for use in vaccines
due to their shared nature between individuals, including
the melanocyte differentiation antigens (MDA)
 
1
 
 gp100,
melanoma antigen recognized by T lymphocytes (MART)-1,
and tyrosinase (2), as well as several proteins in the MAGE
family (1). However, as indicated by results from clinical
trials thus far, inducing therapeutic T cells to these antigens
has been difficult. One reason for the apparent hypore-
sponsiveness of the human immune system to many tumor
antigens may be that they are normal, nonmutated “self”-
proteins, expressed on normal tissues as well as on tumor
cells. An incomplete understanding of the processes of cen-
tral and peripheral tolerance has hampered the develop-
ment of successful cancer vaccines targeting these autoanti-
gens, limiting the use of the growing number of candidate
tumor antigens.
 
1
 
Abbreviations used in this paper:
 
 AA, amino acid; 
 
b
 
-gal, 
 
b
 
-galactosidase;
CM, complete medium; DC, dendritic cell; ER, endoplasmic reticulum;
FPV, fowlpox virus; h, human; m, mouse; MART, melanoma antigen
recognized by T lymphocytes; MDA, melanocyte differentiation; NP, the
nucleoprotein from influenza A; pDNA, plasmid DNA; rVV, recombi-
nant vaccinia virus; TAP, the transporter associated with antigen process-
ing; TRP, tyrosinase-related protein.
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gp100 Is a Murine Tumor Rejection Antigen
 
The absence of an immune response to a defined au-
toantigen can be due to negative selection of self-antigen–
specific T cells during maturation in the thymus, termed
“central” tolerance (4). A low level of autoreactivity is re-
quired for positive selection in the thymus (5, 6).
T cells with low reactivity to autoantigens thus persist.
Mature T lymphocytes with reactivity to self-antigens may
remain in a functionally tolerant state, termed “ignorance”,
if they do not traffic to antigen-bearing cells, or if the target
antigen is not processed and presented to a level that can
trigger the specific TCR. Mature self-reactive T cells that
encounter antigen on normal tissues in the absence of an
activating costimulatory microenvironment can be func-
tionally eliminated by anergization or physically by dele-
tion, thus effecting extrathymic or peripheral tolerance (7, 8).
The mechanisms of breaking tolerance to self-antigens
may be relevant for the induction of immune responses to
tissue differentiation antigens expressed by tumors. To
study requirements for activation of self-reactive, tumor-
specific T cells specific for a naturally expressed antigen, we
targeted gp100, a normal, nonmutated MDA. In humans,
gp100 is expressed both by normal melanocytes and the
majority of malignant melanomas tested (9). CD8
 
1
 
 T lym-
phocytes with reactivity to gp100 have been detected in
patients with metastatic melanoma. The mouse homologue
for gp100, also known as pmel 17, has been cloned previ-
ously (10, 11), and like its human counterpart is normally
expressed in melanocytes in an unmanipulated C57BL/6
mouse as well as in mouse melanomas. We sought to deter-
mine the requirements to break T cell tolerance to a natu-
rally expressed self-antigen. Furthermore, we evaluated the
functional characteristics of autoreactive T cells in the rec-
ognition and destruction of a spontaneous mouse mela-
noma, B16, in vivo.
 
Materials and Methods
 
Animals and Cell Lines.
 
Female C57BL/6 (H-2
 
b
 
) mice, 6–10
wk old, obtained from Frederick Cancer Research Center (Fred-
erick, MD) and maintained in a barrier facility, were used for all
experiments. EL-4 thymoma (H-2
 
b
 
) and the derived 
 
b
 
-galactosi-
dase (
 
b
 
-gal)–transfected clone E22 have been described previ-
ously (12). B16 (H-2
 
b
 
), hereafter named B16.WT, is a spontane-
ous murine melanoma expressing gp100, MART-1, tyrosinase,
tyrosinase-related protein (TRP)-1, and TRP-2 by FACS
 
Ò
 
 and
Western blot analysis (data not shown). B16.B7-1 is a hyperpig-
mented clone of B16.WT that was stably transfected using a
Moloney mouse leukemia virus encoding the gene for B7-1
driven by a LTR promoter. JB/MS is a pigmented, chemically
induced melanoma expressing gp100, provided by Dr. Vincent
Hearing (National Cancer Institute, NIH, Bethesda, MD). 293K
 
b
 
and 293K
 
b
 
D
 
b
 
 are highly transfectable human renal 293 cells stably
transfected with K
 
b
 
 and K
 
b
 
 plus D
 
b
 
, respectively. RMA/S (H-2
 
b
 
)
is a cell line deficient in endogenous peptide loading (13). EL-4,
B16.WT, RMA/S, MCA205, and MC38, a C57BL/6-derived co-
lon carcinoma, were maintained in complete medium (CM; RPMI
1640 with 10% heat-inactivated fetal bovine serum [FBS; Bioflu-
ids, Rockville, MD], 0.03% 
 
l
 
-glutamine, 100 
 
m
 
g/ml streptomycin,
100 
 
m
 
g/ml penicillin, and 50 
 
m
 
g/ml gentamycin sulfate [NIH Me-
dia Center, Bethesda, MD]). B16.B7-1 and E22 were maintained
in CM with 400 
 
m
 
g/ml of bioactive G418. 293K
 
b
 
 and 293K
 
b
 
D
 
b
 
were maintained in DMEM with 10% heat-inactivated FBS, 0.03%
 
l
 
-glutamine, 100 
 
m
 
g/ml streptomycin, 100 
 
m
 
g/ml penicillin, 50
 
m
 
g/ml gentamycin sulfate, and 400 
 
m
 
g/ml of bioactive G418.
 
Peptides.
 
All synthetic peptides were synthesized using regular
F-MOC chemistry. The following synthetic peptides were all syn-
thesized by Peptide Technologies (Washington, D.C.) to a purity
 
.
 
99% by HPLC and amino acid (AA) analysis: KVPRNQDWL,
spanning AAs 25–33 of human (h)gp100; EGSRNQDWL, span-
ning AAs 25–33 of mouse (m)gp100; ASNENMETM, spanning
AAs 366–374 of the nucleoprotein of influenza A (NP);
DAPIYTNV, spanning AAs 96–103 of 
 
Escherichia coli
 
 
 
b
 
-gal (12); and
SIINFEKL, spanning AAs 257–264 of chicken OVA. The NP,
hgp100, and mgp100 peptides are restricted by H-2D
 
b
 
, and the 
 
b
 
-gal
and OVA peptides by H-2K
 
b
 
.
 
Recombinant Viruses.
 
All recombinant vaccinia viruses (rVVs)
used in this study were generated by insertion of the foreign
genes by homologous recombination and subsequent purification
of recombinant progeny as described by Earl et al. (14). rVVs en-
coding the human and mouse gp100 epitopes as minigenes were
constructed using a recombination plasmid, pKT1401, containing
an early promoter driving the signal sequence of the adenovirus
E3/19k protein followed by an additional Ala using code GCA,
resulting in a putative signal peptide cleavage site, and fused to
oligonucleotides encoding the epitope sequences for mgp100,
hgp100, or 
 
b
 
-galactosidase as described above. pKT1401 was re-
combined into the VV locus encoding the small subunit of viral
ribonucleotide reductase. Correct integration was checked by
PCR-based viral genome analysis using primers flanking the viral
locus encoding the small subunit of ribonucleotide reductase (12).
rVVmgp100, rVVmMART-1, rVVmTyr, rVVmTRP-1, and
rVVmTRP-2 were based on the plasmid pSC65, in which the
completely synthetic early/late promoter pS
 
E/liter 
 
drives expression
of the antigen and the early/late promoter p7.5
 
E/liter 
 
drives expres-
sion of the LacZ gene (15). The rVVS
 
E/L
 
b
 
-gal has been described
previously (15, 16). Cloning of the genes for mgp100 and
mMART-1/Melan-A has been described previously (11), and
the cDNAs for hgp100, mTyr, mTRP-1, and mTRP-2 were
gifts from Dr. Y. Kawakami (Surgery Branch, NIH; reference 9),
Dr. H. Yamamoto (Tohoku University, Sendai, Japan; reference
17), Dr. S. Shibahara (Friedrich Miescher Institut, Basel, Switzer-
land; reference 18), and Dr. V. Hearing (Laboratory of Cell Biol-
ogy, NCI, NIH; reference 19), respectively. The rVVhgp100, re-
combinant fowlpox virus (rFPV)hgp100, rFPVmgp100, and rFPV
 
b
 
-
gal were provided by Therion Biologics Corp. (Boston, MA).
Plasmid DNA constructs (pDNA) were based on the pCDNA3
backbone, and encoded hgp100, mgp100, or 
 
b
 
-galactosidase un-
der the control of the CMV promoter. Expression of rVV, rFPV,
and pDNA were confirmed by immunostaining (20) as well as by
Western blot of transfected and infected cells using antisera (21,
22) provided by Dr. V. Hearing. Recombinant adenoviruses were
provided by Dr. Bruce Roberts (Genzyme Corp., Framingham,
MA), and encoded the genes for hgp100, mgp100, or 
 
b
 
-galac-
tosidase under the control of the CMV promoter (11).
 
Generation of gp100-reactive T Cell Line.
 
Mice were vacci-
nated twice at 3-wk intervals by a hand-held helium-driven de-
vice (Geniva Inc., Middletown, WI) with 1 
 
m
 
g of hgp100 DNA
(23), and 3 wk after the second vaccination splenocytes were cul-
tured with rVVhgp100-infected dendritic cells (DCs), generated
as previously described (16) in CM with 30 IU/ml rhIL-2 (a gift
from Chiron Corp., Emeryville, CA) for 7 d, and were subse-
quently restimulated every 7–10 d with 2 
 
3 
 
10
 
5
 
 B16.B7-1 
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(60,000 rad) and 5 
 
3 
 
10
 
6
 
 irradiated splenocytes (1,500 rad) in CM
with 30 IU/ml rhIL-2. T cell clones were derived by limiting dilu-
tion using 0.3 T cells per well cocultured with 4 
 
3 
 
10
 
5
 
 irradiated
splenocytes and 2 
 
3 
 
10
 
4
 
 irradiated B16.B7-1 cells in U-bottomed
96-well plates. The generation of the 
 
b
 
-gal reactive cell line has
been described previously (12). All T cells were used between 5
and 10 d after restimulation. For peptide-induced T cells, mice
were vaccinated as specified in figure legends. Spleens were har-
vested on day 21 after the last vaccination, separated into single cell
suspension, and cultured in T-25 flasks in 15 ml CM at 5 
 
3 
 
10
 
7
 
cells per flask. Peptide was added to a final concentration of 1 
 
m
 
M.
After 6 d of culture, cells were washed in CM and used in a cyto-
kine release assay.
 
Cytokine Release Assay.
 
To determine cytokine release, 5 
 
3
 
10
 
4
 
 target cells per well were added to effector T cells in round-
bottomed 96-well plates at an E/T ratio of 1:1 for established T
cell lines and 5:1 for secondary cultures, and were incubated for
24 h in CM. Supernatants were collected and tested using the
mIFN-
 
g
 
 ELISA kit (Endogen, Cambridge, MA) or the mGM-
CSF ELISA kit (R&D Systems, Minneapolis, MN) according to
manufacturer’s protocol. rVV-, rFPV- and rAd-infected targets
were infected at multiplicities of infection of 
 
.
 
10, 
 
.
 
10, and
 
.
 
100, respectively, incubated for 2 h, and then washed twice in
CM. Peptide-pulsing was performed at 1 
 
m
 
M in CM for 2 h at
37
 
8
 
C and followed by two washes in CM. Transfected targets
were prepared using Lipofectamine (GIBCO BRL, Gaithersburg,
MD) following manufacturer’s guidelines.
 
MHC Class I Stabilization Assay.
 
RMA/S cells were incu-
bated at room temperature for 24 h, pulsed with peptide at the
indicated concentrations for 45 h at room temperature, and then
incubated at 37
 
8
 
C for 4 h to allow turnover of “empty” MHC
class I molecules (13). Cells were then stained with FITC-conju-
gated D
 
b
 
-specific mAb KH95 (PharMingen, San Diego, CA) for
1 h at 4
 
8
 
C and staining was asserted using a FACScan
 
Ò
 
 (Becton
Dickinson, Sunnyvale, CA).
 
Adoptive Transfer Treatment.
 
For adoptive transfer experi-
ments, mice were injected with 2 
 
3 
 
10
 
5
 
 B16 intravenously on
day 0 followed by intravenous injection of the indicated number
of T cells on day 3. rhIL-2 (3 
 
3 
 
10
 
5
 
 IU) was given twice daily in-
traperitoneally for 5 d starting immediately after adoptive transfer.
Alternatively, mice were injected intravenously with the indi-
cated number of T cells, followed 5 d later by 2 
 
3 
 
10
 
5
 
 B16 intra-
venously
 
. 
 
Mice were killed on day 17 after tumor injection and
pulmonary nodules were enumerated. All in vivo experiments
were performed in a blinded, randomized fashion.
 
Results
 
gp100 Is Recognized by Mouse T Cells.
 
To generate gp100-
specific T cells, mice were immunized with mgp100 en-
coded in plasmid DNA or rVV, two vectors with proven
efficacy in the generation of specific T cells (3, 23, 24).
Splenocytes from immunized mice were restimulated in
vitro using syngeneic DCs infected with appropriate rVV,
rFPV, or rAd, and subsequent restimulations were per-
formed with irradiated splenocytes and irradiated B16.B7-1,
a clone of B16 retrovirally transduced to express the co-
stimulatory molecule CD80 (B7-1). None of the cultures
exhibited gp100-specific reactivity when tested by IFN-
 
g
 
release against gp100-positive targets (data not shown). Since
xenogeneic antigen can, in some instances, induce immune
reactivity where the autologous antigen failed (25–27),
mice were immunized with pDNA encoding hgp100.
A CD4
 
2
 
CD8
 
1 lytic T lymphocyte line was generated by
gene-gun administration of pDNA encoding hgp100 fol-
lowed by restimulation of splenocytes ex vivo with DCs
that had been infected with rVVhgp100. After two subse-
quent in vitro restimulations with B16.B7-1 melanoma,
the T cells recognized B16 melanoma, as well as the im-
mortalized normal melanocyte line Melan-A, with a high
degree of specificity (Fig. 1). The EL-4 thymoma and the
MC38 sarcoma were not recognized. However, recogni-
tion could be conferred upon 293 KbDb cells after infection
with rVV encoding either mgp100 or hgp100, but not after
infection with rVV containing any of the other known
MDAs, tyrosinase, TRP-1, or TRP-2.
Antitumor Activity of gp100-specific T Cells. We sought
to evaluate the relevance of mgp100 as a tumor rejection
antigen. To exclude the potential influence of T cells with
a specificity other than gp100, the bulk T cell line was
cloned by limiting dilution. 12 clones were evaluated and
each had reactivities identical to the bulk T cell line shown
in Fig. 1. The gp100-reactive T cell clone (clone no. 9)
was tested in vitro (Fig. 2 A) and in vivo (Fig. 2 B). Mice
bearing 3-d-old B16 pulmonary nodules were infused with
clone no. 9 followed by rIL-2, resulting in a dramatic tu-
mor destruction (P ,0.0001, 4 3 106 b-gal–specific T cells 1
rhIL-2 versus 4 3 106 clone no. 9 T cells 1 rhIL-2), whereas
treatment was ineffective using control b-gal–reactive T cells
or rIL-2 alone (P .0.5 versus no treatment) (Fig. 2 B).
Figure 1. B16 melanoma-reactive T cells specifically recognize non-
mutated gp100. Splenocytes from hgp100-immunized mice were cul-
tured as described in Materials and Methods, and cocultured for 24 h with
various targets shown on the ordinate, including B16 melanoma, the im-
mortalized normal melanocyte line Melan-A, and human 293 kidney cells
expressing the mouse restriction elements H-2Kb and H-2Db infected
with rVV encoding mouse melanocyte differentiation antigens. Superna-
tants were assayed for IFN-g by ELISA. Specific IFN-g release was de-
tected against targets expressing mgp100 or hgp100.280 gp100 Is a Murine Tumor Rejection Antigen
Separate gp100-reactive T cells clones were comparable in
their ability to reject B16 in vivo (data not shown). These
results suggest that gp100 functions as a true tumor rejec-
tion antigen in established murine melanoma.
Identification of a Cross-reactive, MHC Class I–restricted
Epitope in gp100. We sought to understand why T cells
could only be induced by the xenogeneic, human form of
gp100 and not the self sequence. To determine whether
the difference in immunogenicity resided in the actual pep-
tides from gp100 that were recognized by T cells, or in dif-
ferences in sequences outside of those recognized, we char-
acterized the epitopes recognized by the T cell clone. To
identify the MHC class I molecule that restricted gp100
recognition, we used the human renal cell carcinoma line,
293, stably transfected with the mouse restriction elements,
Kb and Db. Both lines were transiently transfected with
plasmids encoding either mouse or human gp100, or with a
control plasmid encoding NP. Only 293 KbDb cells (and
not 293 Kb) cells expressing mgp100 or hgp100 triggered
the release of IFN-g from gp100-reactive T cells, suggest-
ing that Db was the dominant and perhaps only restriction
element for gp100 recognition (Fig. 3 A).
At 626 AAs in length, many possible epitopes in gp100
could be recognized by gp100-reactive T cells. To reduce
the number of candidate peptides, a set of progressively
shorter versions of the gene encoding hgp100 was used
(28). These shortened forms were generated by 39 exonu-
clease digestion or PCR amplification of the original hgp100
cDNA. Fragments were then transfected into 293 KbDb cells
that were used as targets for T cell recognition (Fig. 3 B).
Even the shortest fragment of the hgp100 cDNA, with a
length of 300 bp by gel electrophoresis, conferred a high
degree of recognition upon the 293 transfectants, implying
that a major epitope was located in the first 100 AAs of the
molecule.
To identify the sequence of the epitope, 9-AA-long
peptides were evaluated for their potential to bind to Db
using a computer-generated epitope forecast, based on pre-
viously published peptide binding data, that is designed to
predict binding affinity for a variety of human and mouse
MHC class I alleles (29, 30; and http://bimas.dcrt.nih.gov/
molbio/hla_bind). Based on these predictions, sets of syn-
thetic peptides were made from both hgp100 and mgp100,
which although similar are not identical. When the pep-
tides were added to cultures of gp100-reactive T cells, one
peptide pair, gp10025–33, was recognized with a high degree
of specificity in a GM-CSF release assay (Fig. 3 C).
T Cell Reactivity to gp100 Can Be Induced by Xenoimmuniza-
tion. With the identification of a defined peptide epitope,
we explored the immunological mechanism underlying the
disparate ability of mgp100 and hgp100 to induce gp100-
specific T cells. Mice were vaccinated with rVVmgp100,
encoding mgp100, or rVVhgp100, encoding hgp100, and
splenocytes were isolated after 3 wk and stimulated for 6 d in
vitro with synthetic peptides corresponding to hgp10025–33,
mgp10025–33, or OVA257–264, and then tested in a GM-CSF
release assay (Table 1, first two columns). Splenocytes from
Figure 2. gp100 is a tumor rejection antigen. (A) A clone of bulk
gp100-reactive T cells, clone no. 9, was established by limiting dilution at
0.3 cells/well. Upon coculture, clone no. 9 specifically recognized
B16.WT, B16.B7-1, and JB/MS melanomas, but not control H-2b tumors
EL-4, MCA205, and MC38. Clone no. 9 also recognized MC38 sarcoma
infected with either rVV or rAd encoding hgp100 or mgp100, but not
control rVV or rAd. (B) Specific in vivo reactivity of gp100-specific T
cell clone no. 9 was evaluated by injecting mice with 2 3 105 B16.WT
cells intravenously. 3 d later, the specified numbers of clone no. 9 T cells
were adoptively transferred. 3 3 105 IU rhIL-2 was then given intraperi-
toneally two times daily for 5 d. Mice were killed 18 d after tumor inocu-
lation and pulmonary nodules were enumerated. Transfer of T cell clone
no. 9, but not b-gal–specific T cells or rhIL-2 alone, dramatically reduced
the number of pulmonary nodules in a dose-dependent manner, indicat-
ing that gp100 can function as a tumor rejection antigen in vivo. Addi-
tional independent clones yielded similar results in repeat experiments.281 Overwijk et al.
mice vaccinated with rVVmgp100 and restimulated with
mgp10025–33 or hgp10025–33 peptide failed to develop peptide
reactivity. Conversely, splenocytes from mice vaccinated
with hgp100 and restimulated with either mgp10025–33 or
hgp10025–33 peptide developed reactivity to both peptides.
Similar results were obtained using splenocytes from mice
vaccinated with recombinant fowlpoxvirus or plasmid
DNA (data not shown). These observations indicated that
T cells recognizing mgp100 could be induced exclusively
by xenoimmunization with the hgp100 molecule.
Increased Immunogenicity of hgp100 Is Intrinsic to the MHC
Class I–restricted Epitope. Several mechanisms could ac-
count for the apparent immunological unresponsiveness to
mgp100 and the ability of hgp100 to break it. Nonhomol-
ogous regions of the full-length hgp100 (which is 76%
identical to mgp100 at the AA level; reference 11) could
result in intramolecular epitope-spreading (31, 32) or facili-
tate antibody-mediated antigen capture by APCs (26, 33–
35). Alternatively, sequence differences in the relevant
epitopes or their flanking sequences could result in differ-
ential proteolytic cleavage or transporter associated with
antigen processing (TAP)–mediated transport across the
endoplasmic reticulum (ER) membrane (36). To explore
these possibilities, we constructed a series of rVV-contain-
ing minigenes encoding the relevant 9-AA T cell epitopes
preceded by the E3/19K adenoviral ER-insertion signal se-
quence (ES), previously shown to result in TAP-indepen-
dent transport of antigenic peptides (37), and followed by a
double stop codon. These constructs eliminated differences
in flanking sequences and other nonhomologous regions of
the molecule.
Mice were vaccinated with rVVESmgp100, rVVEShgp-
10025–33, or rVVESb-gal96–103, encoding the 9-AA mgp-
10025–33, hgp10025–33, and b-gal96–103 peptides, respectively
(38). Splenocytes were cultured for 6 d with mgp10025–33
or hgp10025–33 peptides then tested for specificity in a cyto-
kine release assay (Table 1). Reactivities were similar to
those obtained with rVV encoding full-length gp100 mole-
cules: immunization with the mouse minigene gp100 con-
struct failed to induce T cells, whereas immunization with
the hgp100 construct induced T cells that were cross-reac-
tive with both mgp10025–33 and hgp10025–33 peptides. These
results were not consistent with a major role for differential
peptide processing and transport, antibody-facilitated antigen
presentation, or intramolecular immunodominance in the
differential in vivo immunogenicity of mgp100 and hgp100.
MHC Class I–Peptide Interactions and the Immunogenicity of
gp100. To evaluate the relative avidity of the gp100-spe-
cific T cells for the mgp10025–33 and hgp10025–33 epitopes,
we pulsed the peptides onto EL-4 cells (H-2b) (Fig. 4). A
striking difference in the relative T cell activities to the
mgp10025–33 and hgp10025–33 peptides was observed. The
mgp10025–33 peptide was recognized at concentrations as
low as 1029 M, with half-maximal recognition occurring at
about 1028 M, whereas the hgp10025–33 peptide was recog-
nized at concentrations as low as 10211 M. Alanine-substi-
tutions at positions 1, 2, or 3 in either the mouse or human
versions of the synthetic peptides did not substantially alter
recognition by gp100-reactive T cells (Fig. 5 A). Indeed, a
triple-substituted peptide, AAARNQDWL, fully retained
the ability to sensitize EL-4 for recognition. (Fig. 5 B). The
first three AAs could even be deleted and a substantial de-
gree of recognition remained (Fig. 5 B). However, substi-
tution of any of the AAs at positions 4 through 9 abrogated
recognition of both the hgp10025–33 and mgp10025–33 pep-
Figure 3. B16-specific T cells recognize a Db-restricted 9-AA peptide
from gp100. In experiment 1, human 293 kidney cells stably transfected
with Kb and Db were transfected with human and mouse gp100 pDNA
and cocultured for 24 h with gp100-specific T cells. Supernatants were
assayed for IFN-g by ELISA. Specific IFN-g release was detected when T
cells were cocultured with transfected 293 KbDb, but not 293 Kb, indicat-
ing that gp100 recognition was predominantly Db-restricted. In experi-
ment 2, human 293 kidney cells stably transfected with Kb and Db were
transfected with 39 exonuclease truncated constructs of hgp100 pDNA
and cocultured for 24 h with gp100-reactive T cells. Supernatants were
assayed for IFN-g by ELISA. Specific IFN-g release was detected with each
truncated construct, including the 300-bp cDNA fragment, indicating that
a specific immunogenic peptide was located in the 100 NH2-terminal AAs
of the gp100 molecule. In experiment 3, peptides corresponding to the
binding motif for Db were identified in the first 100 residues of the
hgp100 molecule and synthesized together with the corresponding se-
quences from mgp100. Individual peptides were added to gp100-reactive
T cells, and supernatants were assayed for GM-CSF by ELISA. Specific
GM-CSF release was detected with peptide pair gp10025–33, suggesting it
was the 9-AA epitope responsible for the gp100-reactivity of the T cells.282 gp100 Is a Murine Tumor Rejection Antigen
tide variants. To determine the involvement of MHC class
I binding affinity, an MHC class I stabilization assay was
done on RMA/S cells, which lack activity of the TAP
transporters (13). FACSÒ analysis revealed 50% stabilization
of Db by hgp10025–33 peptide at a concentration z100-fold
lower than for mgp10025–33 (Fig. 6). This indicated that the
apparent avidity of gp100-reactive T cells for the hgp10025–33
peptide could be largely attributed to its greater ability to
stabilize the restricting MHC class I molecule, H-2Db.
Self-reactive T Cells Induced with Altered Antigen Function In
Vivo. One major potential use for self-reactive T cells is
their application in cancer treatment. To evaluate the use-
fulness of altered antigen in the development of a synthetic
cancer vaccine capable of eliciting therapeutic T cells, mice
were vaccinated once with rVVhgp100 and restimulated
for three rounds with splenocytes pulsed with 1 mM
mgp10025–33 peptide. CD81 T cells were tested for gp100
recognition by IFN-g release (Fig. 7 A). T cells strongly
recognized both mgp10025–33 and hgp10025–33 peptides, but
not control OVA257–264 peptide, and recognized as well
melanoma B16.WT, B16.B7-1, and JB/MS, a chemically
induced C57BL/6 melanoma. Control H-2b, gp1002 tu-
mor lines were not recognized.
The function of T lymphocytes generated using purely
recombinant and synthetic forms of gp100 were evaluated
by adoptive transfer of T cells to mice bearing tumors es-
tablished for 3 d in vivo. Mice receiving mgp10025–33–spe-
cific T cells experienced a significant reduction in tumor
burden compared with mice receiving control T cells (Fig.
7 B). The survival of these cells was evaluated in vivo by
transfer 5 d before tumor challenge, with T cells retaining
their antitumor activity for this period (Fig. 7 C). This in-
dicated that tumor-specific T cells induced with an anti-
gen-based cancer vaccine can survive in vivo and mediate
efficient tumor destruction.
Discussion
The nonhomologous sequences flanking a MHC-restricted
epitope could influence the immunogenicity of the epitope
through a variety of mechanisms. The full-length hgp100
and mgp100 molecules are 76% identical at the AA level
(11). Xenoimmunization could induce antibodies to non-
homologous determinants on the xenoantigen. When ex-
pressed on the surface of B cells that produce them, these
antibodies could capture the xenoantigen and make it
available for B cell processing and presentation on MHC
class II to activate CD41 T cells (35). This mechanism has
been postulated to play a role in the initiation of human
autoimmune diseases such as SLE, which is largely medi-
ated by CD41 T cells and autoreactive antibodies (25, 34).
Recent data suggest that B cells may cross-present antigen
on MHC class I after capture (39). However, there is a vig-
Table 1. IFN-g Release by Peptide-stimulated Splenocytes from gp100-immunized Mice
Immunization
rVVhgp100 rVVmgp100 rVVEShgp10025–33 rVVESmgp10025–33 Naive
In vitro
stimulation hgp mgp OVA hgp mgp OVA hgp mgp OVA hgp mgp OVA hgp mgp
Peptide targets
None 264 584 236 137 0 51 279 428 5,297 862 1,082 1,324 215 456
hgp 15,120 20,751 250 137 1 0 15,945 11,197 1,267 1,295 1,580 819 229 428
mgp 2,567 19,307 257 94 58 37 940 11,268 1,438 911 847 1,629 215 527
OVA 165 343 144 137 37 208 172 449 300 648 698 2,141 257 478
Mice were vaccinated with indicated rVVs, and splenocytes were isolated 3 wk later and restimulated for 6 d with 1 mg/ml peptide. Subsequent
stimulation of cultured cells with hgp10025–33 or mgp10025–33 peptide resulted in IFN-g release only by splenocytes from mice immunized with
rVVhgp100 or rVVEShgp10025–33. hgp, hgp100 AA 25–33 (KVPRNQDWL); mgp, mgp100 AA 25–33 (EGSRNQDWL); OVA, ovalbumin, AA
257–264 (SIINFEKL). Four repeat experiments yielded similar results; numbers indicate IFN-g (pg/ml) secreted by 2 3 105 CTLs in 24 h; numbers
in bold indicate secretion .3-fold over control peptide.
Figure 4. Recognition of mgp10025–33 and hgp10025–33 peptides at lim-
iting concentrations. EL-4 thymoma cells were incubated with the
mgp10025–33 peptide EGSRNQDWL and hgp10025–33 peptide KVPRN-
QDWL at the concentrations shown on the abscissa for 2 h at 378C,
washed twice, and cocultured for 24 h with gp100-reactive T cells. Su-
pernatants were assayed for IFN-g by ELISA, which was expressed as per-
centage of the maximal release (at 1 mM peptide, as shown on the ab-
scissa). Half-maximal recognition of hgp10025–33 was reached at a
concentration  z1,000-fold lower than that needed for mgp10025–33. Data
shown is an average of two independent experiments.283 Overwijk et al.
orous debate over the ability of B cells to activate “virgin”
T cells (i.e., T cells that have not previously been activated
by antigen) (33, 40). DCs can also capture immune com-
plexes containing xenoantigen through Fc receptors and
present it through MHC class I and class II pathways, induc-
ing de novo activation of autoreactive T cells (41). In this
scenario, the completely autologous mgp100 would not in-
duce such antibodies and thus would fail to be captured and
presented. The involvement of extra-epitope sequences in
the immunogenicity of the human gp100 molecules is not
consistent with the results shown in Table 1 where the im-
munogenicity of human full-length and minimal determi-
nant constructs are compared. In fact, the two constructs
elicit comparable CD81 T cell responses to the 25–33
epitope.
Another mechanism by which xenoimmunization could
enhance immunogenicity is by the processing of a given
epitope. For example, the hgp10025–33 peptide might be
processed more efficiently than the mgp10025–33 peptide,
since the two differ in the three NH2-terminal AAs, as well
as in the AA sequences surrounding the peptides in the
full-length molecule (36, 42). The differences between the
processing of the human and mouse sequences is mini-
mized and possibly eliminated by the use of minigene con-
structs preceded by ER-insertion signal sequences that by-
pass proteasome-mediated peptide liberation as well as
TAP-mediated peptide transport (Table 1).
Indeed, the increased immunogenicity of human gp100
appeared to reside completely within the 9-mer peptide.
The hgp10025–33 peptide differed from its mouse counter-
part in three NH2-terminal AAs. In fact, these three differ-
ences were rather dramatic, with a positively charged lysine
(K) replacing a negatively charged glutamic acid (E), a me-
Figure 5. Fine specificity of gp100-reactive T cells: EL-4 thymoma cells were incubated with either alanine-substituted peptide variants (A) or NH2-
terminally deleted peptide variants (B) for 2 h at 378C, washed twice, and cocultured for 24 h with gp100-reactive T cells. Supernatants were assayed for
GM-CSF by ELISA.
Figure 6. The TAP-deficient cell line RMA-S, expressing “empty”
MHC class I molecules, was incubated with the concentrations shown on
the abscissa with the mgp10025–33 and hgp10025–33 peptides, as well as
control peptides, for 45 min at 258C, then incubated for 4 h at 378C.
Cells were then stained with FITC-conjugated H-2Db–specific mAb
KH95 for 1 h at 48C, and staining was assessed using flow cytometric
analysis and expressed as percentage of the maximal stabilization at 100
mM. The hgp10025–33 peptide stabilized H-2Db molecules at a 100-fold
lower concentration than did the mgp10025–33 peptide.284 gp100 Is a Murine Tumor Rejection Antigen
dium-sized valine (V) replacing a small glycine (G), and
proline (P), which is a cyclic residue and known to reduce
the number of possible conformations due to impaired hy-
drogen bonding, replacing serine (S), which may not in-
duce such a structural distortion. Despite the presence in
both peptides of optimal anchor residues at both dominant
anchor positions, 5 (N) and 9 (L), the difference in the
three NH2-terminal residues resulted in a dramatically in-
creased affinity of the hgp10025–33 peptide for the mouse
MHC class I allele, H-2Db, compared with the mgp10025–33
peptide (Fig. 6). Clearly, the ability of the peptide to stabi-
lize Db molecules on the surface of RMA-S cells could re-
flect the amount of peptide presented on the surface of
APCs, which in turn could determine the activation of T
cell precursors. In retrospect, it was fortuitous that the in-
terspecies differences in the gp100 sequences created such a
high binder, whereas the similarities preserved sufficient T
cell receptor contact residues to allow cross-recognition.
The efficacy of the mechanism described here through
which xenoimmunization induced autoreactive T cells re-
quired that a number of criteria be satisfied. There must be
an MHC-binding epitope in the autologous protein which
is naturally processed and presented that can be recognized
by the available T cell repertoire. Most importantly, a ho-
mologous epitope from the xenogeneic protein must also
be naturally processed and presented, but must be pre-
sented in the context of MHC at a higher density on the
surface of the APCs. The chance that such an epitope will
be found in any give xenoantigen may be small. However,
an understanding of this mechanism clearly points the way
to the rational design of immunogens based on the en-
hancement of the stability of peptide–MHC complexes.
The data presented here suggest that the main difference
between the mgp10025–33 peptide and its hgp10025–33 ana-
logue resides in binding to MHC class I. In human in vitro
studies, modification of the second AA of the hgp100 pep-
Figure 7. rVVhgp100-induced T cells are tumor specific and can treat established melanoma. (A) Mice were vaccinated with 107 rVVhgp100 intrave-
nously 3 wk before splenocytes were isolated and cultured with 1 mM of mgp10025–33 peptide for 6 d, after which the cells underwent two more cycles of
restimulation with mgp10025–33-pulsed splenocytes. The resulting CD42CD81 T cells were cocultured for 24 h with various tumor targets, as well as
MC38 sarcoma infected with indicated rVV or MC38 sarcoma pulsed with 1 mM of peptide, at an E/T ratio of 1:1, and IFN-g release was measured by
ELISA. rVVhgp100-induced T cells were mgp10025–33– and hgp10025–33–specific, and specifically recognized mgp1001 melanomas, as well as MC38 sarcoma
infected with rVVhgp100 or rVVmgp100 but not rVVb-gal, and MC38 sarcoma pulsed with hgp10025–33 or mgp10025–33 peptide, but not OVA257-264 pep-
tide. (B) Mice were injected intravenously with 2 3 105 B16.WT and treated 3 d later with 5 3 106 of the T cells that are shown in A, or with 5 3 106
b-gal–specific T cells, followed by 3 3 105 IU rhIL-2 intraperitoneally twice daily for 5 d. 18 d after tumor inoculation, the number of pulmonary nodules
was specifically reduced by mgp 10025–33–specific T cells. (C) Mice were injected intravenously with 4 3 106 of the T cells that are shown in A, or 4 3 106
b-gal–specific T cells. 5 d later, mice were challenged intravenously with 2 3 105 B16.WT. 18 d after tumor inoculation, the number of pulmonary nodules
was dramatically lower in mice receiving mgp 10025–33–specific T cells, indicating in vivo survival of functional, autoreactive T cells. Two repeat experiments
yielded similar results.285 Overwijk et al.
tide epitope hgp100209–217 to methionine has been shown
to significantly increase its affinity to HLA-A2, leading to
dramatically increased ability to raise gp100-specific T cells
from patient PBLs in vitro (43). The higher affinity peptide
is also more effective in vaccinating patients in vivo, in-
creasing gp100-specific T cell precursor levels, and possibly
resulting in higher treatment response rates (43a). Similarly,
other groups have reported increased immunogenicity of
peptide epitopes with enhanced MHC class I binding (26,
44, 45).
Taken together, these data suggest that there is indeed
unresponsiveness to gp100 in mice. However, the unre-
sponsiveness is relative and can be broken by using a pep-
tide homologue with higher affinity for MHC class I. One
mechanism through which a peptide with higher MHC
class I binding can break tolerance is based on the assump-
tion that T cell tolerance exists to a level of antigen rather
than to the identity of the antigen (44, 46, 47). In the case
of gp100, CD81 T cell precursors with the ability to recog-
nize a certain amount of peptide in the context of MHC
class I are inactivated, through either thymic and/or pe-
ripheral deletion or anergization. The remaining T cells
have TCRs with an affinity that is too low to be triggered
by the levels of gp100 peptide present on melanocytes or
APCs in lymph nodes draining the skin. Therefore, these T
cells are never activated, deleted, or anergized. Instead,
they remain “ignorant” of MHC class I with mgp10025–33
peptide. A vaccination with autologous mgp100 will not
trigger these T cells unless the vaccine is able to signifi-
cantly raise the amount of peptide–MHC class I complex
on professional APCs to a level high enough to surpass the
TCR threshold. Only then do the T cells become acti-
vated. We are currently evaluating the clinical efficacy of
antitumor effects of gp100-based cancer vaccines that con-
tain epitopes with enhanced stability of peptide–MHC
complexes.
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